Hemodialysis Urological and Genital Diseases
Conditions
Interventions
Patients were divided into two cohorts: HDx and HF-HD. The use of HDx, enabled by the Theranova dialyzer, was dependent on the availability of these membranes at the clinical sites, and the prescripti
Sponsors
Baxter International, Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients over 18 years of age. 2. Patients diagnosed with chronic kidney disease (CKD) in renal failure with more than 90 days in chronic hemodialysis. 3. Receiving HD at least 3 times per week and with a minimum duration of 4 hours per session. 4. Being treated in one of the 12 renal clinics of the Baxter Renal Care Services (BRCS) network included in the study, in the cities of Bucaramanga, Barranquilla, Medellín, Bogotá, Ibague, Armenia, Cali. 5. Being covered by one of the following health insurers: Nueva EPS, Compensar, Comparta, Comfenalco Valle and Mutualser
Exclusion criteria
Exclusion criteria: 1. Pregnant women. 2. Patients whose clinical history does not have sufficient information to establish their nutritional diagnosis. 3. Having a high comorbidity, measured as a Charlson comorbidity index > 8 and patients who are not expected to survive more than 6 months. 4. Metastatic disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Albumin serum (bromocresol green) was measured each six month ( baseline, 6,12,18,24,30,36,42,48 months) 2.Protein-energy wasting (PEW) was measured by applying the four diagnostic criteria: 2.1. altered serum biochemistry indicated by a serum albumin level of <3.8 g/L or total cholesterol <100 mg/dL 2.2. decreased body mass status identified by a body mass index (BMI) of <23 kg/m² or <10% total body fat 2.3. muscle wasting defined by the lean tissue index 2.4. low dietary protein intake determined by the normalized protein equivalent of a total nitrogen appearance of <0.8 g/kg/day. ( baseline, 6,12,18,24,30,36,42,48 months) 3.Hospitalization: defined as any hospital admission event lasting 24 hours or more. Recording the main diagnosis with ICD 10 code nomenclatura. Chronological record from day 1 to month 48 of follow-up. 4.Mortality: Death during follow-up in the study. Recording the diagnosis cause with ICD 10 code nomenclatura. Chronological record from day 1 to month 48 of follow-up. 5.Fatal major cardiovascular evento: Recording the diagnosis cause with ICD 10 code nomenclatura. Chronological record from day 1 to month 48 of follow-up. See Appendix 3 of the protocol. | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
Colombia
Contacts
Public ContactJuan Carlos Mario Castillo
Outcome results
None listed